Equities analysts forecast that resTORbio, Inc. (NASDAQ:TORC) will announce ($0.40) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for resTORbio’s earnings, with the highest EPS estimate coming in at ($0.39) and the lowest estimate coming in at ($0.40). The business is scheduled to announce its next earnings results on Thursday, November 8th.
According to Zacks, analysts expect that resTORbio will report full-year earnings of ($1.75) per share for the current fiscal year, with EPS estimates ranging from ($2.03) to ($1.56). For the next fiscal year, analysts anticipate that the business will report earnings of ($2.36) per share, with EPS estimates ranging from ($2.88) to ($2.03). Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that follow resTORbio.
resTORbio (NASDAQ:TORC) last released its earnings results on Thursday, August 9th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.06).
resTORbio stock opened at $11.37 on Friday. The company has a market capitalization of $317.48 million and a PE ratio of -1.34. resTORbio has a fifty-two week low of $7.55 and a fifty-two week high of $21.10.
Several hedge funds have recently bought and sold shares of TORC. Citadel Advisors LLC acquired a new stake in shares of resTORbio during the first quarter worth approximately $110,000. Bank of New York Mellon Corp boosted its holdings in shares of resTORbio by 76.7% during the second quarter. Bank of New York Mellon Corp now owns 21,693 shares of the company’s stock worth $199,000 after purchasing an additional 9,413 shares during the period. Wedbush Securities Inc. acquired a new stake in shares of resTORbio during the second quarter worth approximately $236,000. Bank Hapoalim BM acquired a new stake in shares of resTORbio during the second quarter worth approximately $269,000. Finally, Schwab Charles Investment Management Inc. acquired a new stake in shares of resTORbio during the first quarter worth approximately $270,000. Institutional investors and hedge funds own 43.28% of the company’s stock.
resTORbio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems.
Featured Article: Diversification
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for resTORbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for resTORbio and related companies with MarketBeat.com's FREE daily email newsletter.